🔴 HCW Biologics is trading 10.1% down in pre-market

HCW Biologics is trading at $1.33, down 10.1%, with no company-specific explanation identified for the pre-market decline.

• This compares with the provided October 12 close of $1.48.
• The latest company news, dated October 9, said its FDA-guided IND application for a solid-tumor T-cell engager remains on track for the first half of 2027; that update does not establish the cause.
• Available market context is mixed; recent financing and registration filings are background, not confirmed triggers.